By Ludwig Burger
(Reuters) – Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from drugmakers.
First-half core earnings – adjusted for interest, tax, depreciation and amortisation – (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday. That was above an analyst consensus of about 940 million.
(Reporting by Ludwig Burger, Editing by Miranda Murray)
